The trajectory of Sildenafil presents a intricate picture for shareholders. While the initial release generated substantial profits, the end of its exclusive rights opened the floodgates to generic competitors, https://agnesqphf103950.ivasdesign.com/62973105/the-copyright-and-big-pharma-a-risky-investment